Protara Therapeutics Inc. (TARA), a clinical-stage company developing transformative therapies for cancer and rare diseases, is set to deliver a pivotal presentation on April 26, 2025, at the American Urological Association Annual Meeting, featuring new data from the ongoing ADVANCED-2 trial of TARA-002.
ADVANCED-2 is a phase II trial of investigational cell therapy TARA-002 in adults with high-grade non-muscle invasive bladder cancer.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com